Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.30 |
| ▸ | GCGR | P47871 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10071781 | 0.94 | CNR1 (0.38) | CNR1CNR2LTB4RACHECSNK1E | |
| SCHEMBL407639 | 0.77 | CTSK (0.37) | CNR2KMT2A | |
| SCHEMBL402987 | 0.75 | TLR8 (0.40) | CNR1CNR2ACHEDHFRMEN1 | |
| SCHEMBL10041933 | 0.73 | TLR8 (0.43) | CNR1CNR2DHFRMEN1KMT2A | |
| SCHEMBL10071168 | 0.71 | CYP17A1 (0.39) | CNR2KMT2A | |
| SCHEMBL20086471 | 0.69 | GRIA4 (0.45) | CNR1CNR2CSNK1EMEN1KMT2A | |
| SCHEMBL8683367 | 0.68 | SOAT1 (0.42) | CSNK1ESOAT1MEN1KMT2ANPSR1 | |
| SCHEMBL7855771 | 0.68 | TSHR (0.38) | CSNK1EMEN1KMT2A | |
| SCHEMBL2878717 | 0.68 | TSHR (0.38) | CSNK1EMEN1KMT2A | |
| SCHEMBL11538867 | 0.68 | TSHR (0.38) | CSNK1EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065432-A1 | ELECTROACTIVE MATERIALS | E.I DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065432-A1 | ELECTROACTIVE MATERIALS | NAT1, ADRA1D, ADRA1B | CNR1 228/4885CNR2 338/4885LTB4R 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.